C21orf77 Activators encompass a diverse array of chemical compounds that indirectly stimulate the functional activity of C21orf77 through various signaling pathways. Forskolin and Ionomycin, for example, enhance intracellular levels of cAMP and calcium respectively; the former activates protein kinase A (PKA) while the latter can stimulate calcium-dependent kinases. These activations may result in phosphorylation events that include C21orf77, thereby enhancing its activity. Similarly, PMA, a PKC activator, and Sphingosine-1-phosphate (S1P), a bioactive lipid, both activate their respective pathways, which can lead to the phosphorylation and consequent activation of C21orf77. Additionally, EGCG, through its kinase inhibition, and LY294002, a PI3K inhibitor, can shift signaling dynamics to favor pathways that activate C21orf77 if it is within their scope of influence. The selective inhibition of MEK1/2 by U0126 and p38 MAPK by SB203580 might also divert signaling towards mechanisms involving C21orf77, leading to its activation.
Furthermore, the functional activity of C21orf77 is influenced by compounds that modulate intracellular calcium levels and kinase activity. A23187 and Thapsigargin both act as calcium ionophores, with the latter specifically inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), thereby potentially enhancing the activation of C21orf77 through calcium-dependent signaling pathways. Staurosporine, despite its broad-spectrum kinase inhibition, may preferentially activate signaling pathways that upregulate C21orf77 by inhibiting kinases that otherwise suppress it. Genistein's role as a tyrosine kinase inhibitor might also reduce competitive phosphorylation events, thereby creating a signaling environment conducive to the activation of C21orf77. Collectively, these activators work through distinct yet interconnected biochemical mechanisms, all converging on the enhancement of C21orf77's activity without direct interaction, but rather by influencing the signaling landscape in which C21orf77 operates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can lead to phosphorylation of proteins involved in various signaling pathways, potentially including those that C21orf77 is part of, resulting in the activation of C21orf77. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent kinases and phosphatases, potentially leading to the activation of C21orf77. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain types of kinases. Inhibition of competitive kinases may reduce phosphorylation-based inactivation of target proteins, possibly leading to enhanced activity of C21orf77. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. Inhibition of PI3K can modulate the AKT signaling pathway, potentially leading to activation of proteins such as C21orf77 if it is involved in this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which impacts the MAPK/ERK pathway. This inhibition could shift the balance of signaling towards pathways in which C21orf77 is active, leading to its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore that increases intracellular calcium, activating calcium-dependent signaling pathways, potentially leading to the activation of C21orf77. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, which may be involved in signaling pathways that include C21orf77, leading to its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 may lead to the activation of alternative signaling pathways that could engage and activate C21orf77. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). This disruption can activate calcium signaling pathways, potentially leading to the activation of C21orf77. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. While it generally inhibits kinases, it can also lead to the activation of specific pathways by inhibiting kinases that negatively regulate proteins like C21orf77. | ||||||